Fig. 6: Druggable candidates, particularly TAS102, could be a new selective chemotherapy for ovarian cancer.
a The heatmap of expression signature of selected druggable candidates between tumours and fallopian tissues. Annotation indicates the coverage (detected frequency) and cox analysis in non-C2 HGSC tumours and approved drugs for each gene. The association of TYMP protein expression with OS in non-C2 (C1/C3/C4) patients of Xiangya OC proteomics (b) and CPTAC2016 OC proteomics (c). Log-rank test. d The association of TYMP protein expression with OS in C2 patients of Xiangya OC proteomics. Log-rank test. e Schematic diagram of NOD-SCID mice implant PDX model. Time schedule and concentration (150 mg per kg, oral) of treated TAS102 as indicated. f Growth curves of PDX tumours treated with 0.5% HPMC or TAS102. The mice with tumours were randomly divided into two groups treated with 0.5% HPMC or TAS102 after the tumour volumes reaching to 60–100 mm3. Tumour volumes were measured at indicated time points. (n = 4, error bars, SEM; ***P < 0.001, two-sided, unpaired t test). Tumours were isolated from individual mice at the end of the treatments (right). g Representative images of IHC staining with cell proliferation marker Ki67, TYMP, apoptosis marker caspase 3, and HE in tumour samples derived from PDX in NOD-SCID mice. Scale bar, 100 μm. h Quantitation of the histologic score (H score) of indicated markers from three random areas of four individual mice in different groups as indicated (***P < 0.001, **P < 0.01, two-sided, unpaired t test). i C57BL/6j mice were orthotopically inoculated with ID8Luc+ cells with or without TYMP expression and subsequently treated with HPMC or TAS102 (150 mg per kg, oral). Representative luminescent images and abdominal metastases (right) of mice bearing vector or TYMP overexpressing ID8Luc tumour treated with HPMC (Control) or TAS102 at day 21 are shown.j The luciferin photon count of mice treated with HPMC or TAS102 at day 21. (*P < 0.05, two-sided, unpaired t-test). k Representative images of orthotopic tumours isolated from individual mice at the end of the treatments.
